Needham & Company LLC assumed coverage on shares of Legend Biotech (NASDAQ:PCVX) in a report issued on Tuesday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $40.00 target price on the stock.
Separately, Cantor Fitzgerald began coverage on shares of Legend Biotech in a research report on Tuesday. They set an overweight rating and a $55.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and an average target price of $42.25.
NASDAQ PCVX opened at $29.35 on Tuesday. Legend Biotech has a fifty-two week low of $17.80 and a fifty-two week high of $36.50.
Legend Biotech Company Profile
Vaxcyte, Inc a biopharmaceutical company, develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate, and complex antigen-based vaccines. The company has a license to Sutro Biopharma's Xpress CF platforms for cell free protein synthesis and site-specific conjugation. Vaxcyte, Inc was formerly known as SutroVax, Inc and changed its name to Vaxcyte, Inc in May, 2020.
Featured Article: How does a security become overbought?
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.